Laying Out Discovery & Development of STRO-006: a Differentiated Topo1-ADC Targeting Integrin Beta-6
- Unveiling integrin beta-6 target selection rationale alongside STRO-006 development
- Exploring STRO-006 in vitro and in vivo pharmacology data and preclinical profile across CDX and PDX models
- Assessing emerging ADC safety data of STRO-006